[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201991768A1 - Слитые белки на основе фактора ix и способы их получения и пути применения - Google Patents

Слитые белки на основе фактора ix и способы их получения и пути применения

Info

Publication number
EA201991768A1
EA201991768A1 EA201991768A EA201991768A EA201991768A1 EA 201991768 A1 EA201991768 A1 EA 201991768A1 EA 201991768 A EA201991768 A EA 201991768A EA 201991768 A EA201991768 A EA 201991768A EA 201991768 A1 EA201991768 A1 EA 201991768A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor
fusioned
methods
ways
producing
Prior art date
Application number
EA201991768A
Other languages
English (en)
Inventor
Арьян Ван Дер Флир
Чжицянь Лю
Дэвид Р. Лайт
Экта Сет Чхабра
Туняо Лю
Роберт Т. Питерс
Джон Кульман
Айман Исмаил
Original Assignee
Байоверетив Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоверетив Терапьютикс Инк. filed Critical Байоверетив Терапьютикс Инк.
Publication of EA201991768A1 publication Critical patent/EA201991768A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В настоящем изобретении представлены слитые белки на основе фактора IX (FIX), содержащие по меньшей мере один гетерологичный компонент, такой как XTEN. В настоящем изобретении дополнительно раскрыты способы получения и применения слитых белков на основе FIX.
EA201991768A 2017-01-31 2018-01-31 Слитые белки на основе фактора ix и способы их получения и пути применения EA201991768A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31
PCT/US2018/016277 WO2018144623A1 (en) 2017-01-31 2018-01-31 Factor ix fusion proteins and methods of making and using same

Publications (1)

Publication Number Publication Date
EA201991768A1 true EA201991768A1 (ru) 2020-01-22

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991768A EA201991768A1 (ru) 2017-01-31 2018-01-31 Слитые белки на основе фактора ix и способы их получения и пути применения

Country Status (19)

Country Link
US (1) US20210238259A1 (ru)
EP (1) EP3576762A1 (ru)
JP (1) JP2020505424A (ru)
KR (1) KR20190112763A (ru)
CN (1) CN110831613A (ru)
AR (1) AR110871A1 (ru)
AU (1) AU2018215092A1 (ru)
BR (1) BR112019015569A2 (ru)
CA (1) CA3051862A1 (ru)
CL (1) CL2019002155A1 (ru)
CR (1) CR20190389A (ru)
EA (1) EA201991768A1 (ru)
IL (1) IL268234A (ru)
MA (1) MA47416A (ru)
MX (1) MX2019009063A (ru)
PH (1) PH12019501765A1 (ru)
SG (1) SG11201906788XA (ru)
TW (1) TW201831521A (ru)
WO (1) WO2018144623A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0218713B1 (en) 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DE122010000006I2 (de) 1989-02-21 2012-06-21 Univ Washington Modifizierte formen von fortpflanzungshormonen.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69332859T2 (de) 1992-11-13 2003-12-18 Idec Pharmaceuticals Corp., San Diego Konsensus-kozak-sequenzen zur säugetier-exprimierung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2283740C (en) 1997-03-14 2006-06-27 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
WO2003020764A2 (en) 2001-09-04 2003-03-13 Merck Patent Gmbh Modified factor ix
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
HRP20070268B1 (hr) 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
CA2663352A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
ES2422007T3 (es) 2007-06-21 2013-09-06 Univ Muenchen Tech Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro
EP2209487A4 (en) 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
KR20110005862A (ko) 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
AR071478A1 (es) 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
SI2440241T1 (sl) 2009-06-08 2017-11-30 Amunix Operating Inc. Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
CN102741275B (zh) * 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
ME02964B (me) 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
SG10201505218YA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Factor ix polypeptides and methods of use thereof
EP3674410A1 (en) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3331608A4 (en) * 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHOD FOR THE PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
US20210238259A1 (en) 2021-08-05
WO2018144623A1 (en) 2018-08-09
CN110831613A (zh) 2020-02-21
EP3576762A1 (en) 2019-12-11
IL268234A (en) 2019-09-26
MA47416A (fr) 2019-12-11
JP2020505424A (ja) 2020-02-20
AR110871A1 (es) 2019-05-08
CR20190389A (es) 2019-11-26
CA3051862A1 (en) 2018-08-09
KR20190112763A (ko) 2019-10-07
SG11201906788XA (en) 2019-08-27
BR112019015569A2 (pt) 2020-03-17
TW201831521A (zh) 2018-09-01
CL2019002155A1 (es) 2020-02-21
AU2018215092A1 (en) 2019-08-29
MX2019009063A (es) 2019-10-21
PH12019501765A1 (en) 2020-03-16

Similar Documents

Publication Publication Date Title
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
CY1123642T1 (el) Αντισωματα enanti-pd-1
MY198059A (en) Anti-ox40 antibodies and their uses
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA202092692A1 (ru) Аналоги рапамицина и их применения
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA201591421A1 (ru) Препараты полипептида фактора ix
MX2021007141A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
MX2021007143A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
EA201991768A1 (ru) Слитые белки на основе фактора ix и способы их получения и пути применения
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение
CL2021002836A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)
EA201992593A1 (ru) Варианты сконструированной лигазы
SA518391078B1 (ar) (tslp) أجسام مضادة رابطة لليمفوبويتين السدوي الصعتري وطرق لاستخدام الأجسام المضادة